Navigation Links
Lipid blocks influenza infection
Date:11/9/2011

A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.

"Supplemental POPG could be an important, inexpensive and novel approach for the prevention and treatment of influenza and other respiratory virus infections," said Dennis Voelker, PhD, Professor of Medicine, and senior author in the report, published online in the American journal of Respiratory Cell and Molecular Biology.

Influenza infects millions of people across the globe, killing 500,000 each year. Vaccines are highly effective, but must be reformulated each year to counter new viral strains. Two classes of drug are currently available to treat established influenza infections, although widespread resistance has developed against one class and is developing against the other.

Several proteins that inhibit viral activity have been identified in the fluid lining the lungs. Until recently, however, the antiviral role of POPG (palmitoyl-oleoyl-phosphatidylglycerol) has been unknown. Previous research by Dr. Voelker, Mari Numata, MD, PhD, and their colleagues demonstrated that POPG reduces inflammation in the lung and prevents infection by respiratory syncytial virus.

In the most recent study, the researchers looked at the ability of POPG to inhibit infection by two strains of influenza, H1N1-PR8 and H3N2. They found that POPG suppressed inflammatory responses, viral propagation and cell death normally associated with influenza infection.

In mice, POPG also suppressed viral infection and replication, and markedly reduced the inflammatory response to the virus. There were no observable deleterious effects of POPG in animal behavior or histopathology.

"Lipids such as POPG, offer potential advantages over antiviral proteins, because they are less likely to elicit unwanted immune responses, are more chemically stable and less expensive to manufacture than proteins," said Dr. Numata, an instructor at National Jewish Health, and lead author on both the RSV and influenza papers. "Because POPG is effective against at least two different viruses, it also seems likely that a single mutation, which can make influenza vaccines and current drugs ineffective, is unlikely to have the same effect on POPG's action."

The researchers showed that POPG works by binding strongly to viral particles, which prevents attachment and infection of cells. This means that POPG works best if given before an infection occurs.

It has potential, however, to work after an infection has begun by inhibiting spread of the virus to uninfected cells. The success of POPG treatment after a virus infection has been established depends on keeping the lipid levels high for an extended period. At present it is difficult to maintain high levels of POPG in mice because of their rapid metabolisms and rapid respiratory rate.

"We believe POPG may prove effective both before and after an infection has occurred," said Dr. Voelker. "Our initial results suggest that it may be possible to maintain therapeutic levels in the body with a reasonable dosing scheme, and we are investigating that now."


'/>"/>
Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Related medicine news :

1. New drug candidate reduces blood lipids
2. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
3. International summit held to stimulate collaborative clinical research on antiphospholipid syndrome
4. Researchers identify the metabolic signaling pathway responsible for dyslipidemia
5. South Carolina researcher wins Avanti Award in Lipids
6. CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive
7. New advances in lipid genetics lead to better detection and prevention of major diseases
8. New study shows soy protein improves lipid profile in healthy individuals
9. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
10. Researchers create first molecule-blocks key component of cancer genes on-off switch
11. Researchers create first molecule blocks key component of cancer genes on-off switch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... Remote Medical Technologies (RMT), the leader ... with their iMedHD2™ Portable Teleultrasound System. Compatible with any ultrasound ... HD, dynamic, streaming ultrasound images and video to one or more distant locations ...
(Date:1/19/2017)... City, Utah (PRWEB) , ... January 19, 2017 ... ... Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen ... to provide a condensed version of the clinic’s leading recovery program. , ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... by the American Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. ... Institutes of Health, Dr. Li completed his internship in internal medicine at the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics ... provides a modern CTMS workflow designed to seamlessly integrate and streamline the way ... to a single page, maximizing usability and improving efficiency significantly for users – ...
(Date:1/19/2017)... San Antonio, Texas (PRWEB) , ... January 19, 2017 , ... ... entering the GenCure Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 ... media accounts. The competition begins Feb. 1, and the deadline is May 31, with ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, Inc. ... company specializing in the treatment of non-melanoma skin ... with superficial radiation therapy, today announced that it ... 2016 financial results on Thursday, February 2, 2017 after ... hold a conference call with the investment community ...
Breaking Medicine Technology: